Electronic Supplementary Information (ESI)

Preparation of hyaluronic acid-coated polymeric micelles for nasal vaccine delivery

Kengo Suzuki¹, Yuta Yoshizaki^{2†}, Kenta Horii¹, Nobuo Murase², Akinori Kuzuya^{1,3}, Yuichi Ohya^{1,3*}

¹ Faculty of Chemistry, Materials, and Bioengineering, Kansai University, 3–3–35 Yamate, Suita, Osaka 564–8680, Japan
 ² Organization for Research and Development of Innovative Science and Technology (ORDIST), Kansai University, 3–3–35 Yamate, Suita, Osaka 564–8680, Japan

³Kansai University Medical Polymer Research Center (KUMP-RC), Kansai University, 3–3–35 Yamate, Suita, Osaka 564–8680, Japan

[†]Present address: Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan

*Corresponding author: Yuichi Ohya

e-mail: yohya@kansai-u.ac.jp, TEL +81-6-6368-0818, FAX: +81-6-6339-4026

INDEX

Preparation of PLys⁺-b-PLLA
Figure S1. ¹H NMR spectrum of HO-PLLA.
Figure S2. ¹H NMR spectra of Boc-NH-PLLA and H₂N-PLLA.
Figure S3. ¹H NMR spectra of PLys(Z)-b-PLLA and PLys⁺-b-PLLA.
Figure S4. Quantification of dendritic cell markers (CD11c⁺) of the collected bone marrow cells using a flow cytometer after treatment with R10 medium containing 10 ng/mL GM-CSF.
Figure S5. FCA of BMDCs with or without PE-labelled anti-MHC class II antibody staining.
Figure S6. Flow cytometric analysis (FCA) for BMDCs incubated with HA-micelle(OC) or Dex-micelle(OC) containing Rhodamine-labelled OVA and FAM-labelled CpG-DNA at 37°C for 4 h.

Table S1. Sequences of qPCR primers.

Preparation of PLys⁺-b-PLLA

Materials

L-Lactide, 1-dodecanol, Sn(Oct)₂, *N*-(*tert*-butocycarbonyl)glycine (Boc-Gly-OH), *N*,*N'*-dicyclohexylcarbodiimide (DCC), 4-(dimethylamino)pyridine (DMAP), trifluoroacetic acid (TFA), triethylamine (TEA), 25% HBr/AcOH, diethyl ether, chloroform, methanol, *N*,*N*-dimethylformamide (DMF), chloroform-*d* (CDCl₃), dimethyl sulfoxide (DMSO)-*d*6 and other reagents were purchased from Fujifilm Wako Pure Chemical Corporation (Japan). *N*-Benzyloxycarbonyl-L-lysine N-carboxy anhydride (Lys(Z)-NCA) was purchased from Hodogaya Contract Laboratory Co. Ltd. (Japan). Hyaluronic acid sodium salt (Mw = \sim 90,000 Da) was obtained from Kibun Food Chemifa Co., Ltd. (Japan). Water was purified using Millipore Elix UV3 direct-Q UV (Merck, Darmstadt, Germany). *Measurements*

¹H-Nucleic magnetic resonance (NMR) spectra were obtained on a JNM-ECS400 or GSX-400 spectrometer (JEOL, Tokyo, Japan). The molecular weight was measured by size-exclusion chromatography (SEC) (Tosoh GPC-8020 series system; Tosoh TSKgel α -5000 or Tosoh GMH_{HR}-H(S), Tosoh Corporation, Tokyo, Japan).

Synthesis of polylactide with amino-terminal (H₂N-PLLA)

We synthesised polylactide with an amino-terminal (H₂N-PLLA) by bulk ring-opening polymerisation of L-lactide, condensation with Boc-Gly-OH, and subsequent deprotection according to previous literature^{36,37}.

First, L-lactide (69.4 mmol, 10.0 g), 1-dodecanol (2.31 mmol, 430 mg), and Sn(Oct)₂ (69.4 µmol, 28.1 mg) were placed in a flask with stopcock and dried under reduced pressure for 6 hours. After melting in an oil bath at 150°C, bulk ring-opening polymerisation was carried out at 120°C for 9 h. The reaction mixture was dissolved in a small amount of chloroform and re-precipitated using a mixture of chloroform and diethyl ether (1:20). The precipitate was collected via suction filtration and dried under reduced pressure. Polylactide with free OH terminal (and dodecyl ester terminal) (HO-PLLA) was obtained as a white solid (yield: 88%). ¹H-NMR spectrum is shown in **Figure S1**. $M_w = 7,100, M_n = 5,500, M_w/M_n$: 1.30 estimated by SEC.

Boc-Gly-OH (3.0 mmol, 0.53 g) and DCC (3.7 mmol, 0.76 g) were separately dissolved in dry methylene chloride (2.17 mL for Boc-Gly-OH and 3.05 mL for DCC). The DCC solution was added dropwise to the Boc-Gly OH solution, and the mixture was stirred for 1 h in an ice bath. In another flask, HO-PLLA (0.75 mmol, 3.00 g) and DMAP (0.41 mmol, 50.0 mg) were dissolved in dry methylene chloride (20.5 mL). The solution of HO-PLLA and DMAP was added to the Boc-Gly-OH and DCC solution at room temperature. The mixture was stirred for 24 h, and the dicyclohexylurea residue was removed by suction filtration. The product (Boc-NH-PLLA) was dissolved in a small amount of chloroform and re-precipitated using chloroform and diethyl ether (1:20). The precipitate was collected via suction filtration and dried under reduced pressure (Yield: 81%). ¹H-NMR spectrum is shown in **Figure S2**. $M_w = 6,500$, $M_n = 5,700$, $M_w/M_n = 1.14$ estimated by SEC.

Boc-NH-PLLA (542 µmol, 2.21 g) in a flask was dried for 4 h under reduced pressure and dissolved in dry methylene chloride (15 mL) under a nitrogen atmosphere. TFA (81 mmol, 6.2 mL) was then added to the flask and stirred for 1 h at 0 C in an ice bath. After the reaction, reprecipitation was performed three times with chloroform and hexane (1:20). A white solid was obtained after drying under reduced pressure. The product (H₂N-PLLA TFA salt) was dissolved in dry methylene chloride (12 mL), and TEA was added to the solution in an ice bath for desalting. The reaction mixture was stirred for 1 min. Reprecipitation was performed thrice with chloroform and hexane (1:20).

After drying under reduced pressure, H₂N-PLLA was obtained as a white solid (yield: 79%). The ¹H NMR spectrum is shown in **Figure S2**. $M_w = 5,700$, $M_n = 5,000$, $M_w/M_n = 1.31$ estimated by SEC.

Synthesis of PLys+-b-PLLA

The synthesis of the diblock copolymer of poly(L-lysine) and polylactide, PLys⁺-*b*-PLLA, was carried out by ringopening polymerisation of Lys(Z)-NCA using the obtained H₂N-PLLA as a macro-initiator and subsequent deprotection according to a method reported previously^{36,37}.

H₂N-PLLA (386 µmol, 1.35 g) and Lys(Z)-NCA (11.6 mmol, 3.54 g) were dried at reduced pressure for 7 h. H₂N-PLLA was dissolved in dry chloroform (20.2 mL) in two-necked flasks and stirred in an oil bath at 40°C. Then, a Lys(Z)-NCA solution in chloroform (3.4 mL) was added to initiate the polymerisation. The reaction was carried out at 40°C for 24 h under a nitrogen atmosphere. After the reaction, the products were reprecipitated three times using a mixture of diethyl ether and methanol (10:1), owing to the poor solubility of the product in this mixture. The precipitate was collected via centrifugation and dried under reduced pressure to obtain a white solid of PLys(Z)-*b*-PLLA (yield: 70%). ¹H-NMR spectrum is shown in **Figure. S3**. $M_w = 13,000$, $M_n = 10,000$, $M_w/M_n = 1.3$ estimated by SEC.

The benzyloxycarbonyl(Z) group of PLys(Z)-*b*-PLLA was removed as follows: PLys(Z)-*b*-PLLA (56.7 μ mol, 681 mg) was dried under vacuum overnight and then dissolved in TFA (6.1 mL) in a flask equipped with a calcium chloride tube. HBr/AcOH (25%, 18.7 mmol, 4.4 mL (10 eq of Z group)) was added to this solution. The ice-cooled reaction mixture was stirred at 0°C for 30 min. After the reaction, the products were precipitated with diethyl ether. The precipitate was collected *via* centrifugation and dried under reduced pressure to obtain a white solid (yield: 80%). The degree of deprotection of the Z group was estimated to be 96% using ¹H-NMR spectroscopy. ¹H-NMR spectrum is shown in **Figure. S3**. $M_w = 9,000$, $M_n = 7,500$, $M_w/M_n = 1.20$ estimated by SEC.



Figure S1. ¹H NMR spectrum of HO-PLLA. (Solvent: CDCl₃)



Figure S2. ¹H NMR spectra of Boc-NH-PLLA and H₂N-PLLA. (Solvent: CDCl₃)



Figure S3. ¹H NMR spectra of PLys(Z)-*b*-PLLA and PLys⁺-*b*-PLLA. (Solvent: CDCl₃)



Figure S4. Quantification of dendritic cell markers (CD11c⁺) of the collected bone marrow cells using a flow cytometer after treatment with R10 medium containing 10 ng/mL GM-CSF.



Figure S5. FCA of BMDCs with or without PE-labelled anti-MHC class II antibody staining. Cells were incubated with HA micelles (OC), an aqueous solution of OVA and CpG-DNA or PBS in RPMI-1640 containing 5% FBS for 24 h at 37°C.



Figure S6. Flow cytometric analysis (FCA) for BMDCs incubated with HA-micelle(OC) or Dex-micelle(OC) containing Rhodamine-labelled OVA and FAM-labelled CpG-DNA at 37°C for 4 h. (A) Rhodamine B detection (OVA), (B) FAM detection (CpG-DNA).

Table S1.	Sequences	of qPCR	primers
-----------	-----------	---------	---------

Prir	mers	Sequences	References	
IL-4	forward	5'-ATGGGTCTCAACCCCCAGCTAGT-3'	[1]	
	reverse	5'-GCTCTTTAGGCTTTCCAGGAAGTC-3'		
IFN-γ	forward	5'-TGAACGCTACACACTGCATCTTGG-3'	[2]	
	reverse	5'-CGACTCCTTTTCCGCTTCCTGAG-3'		
β-Actin	forward	5'-TGGAATCCTGTGGCATCCATGAAA-3'	[2]	
	reverse	5'-TGAACGCTACACACTGCATCTTGG-3'		

[1] M. Galdiero, A. Marcatili, G. Cipollaro del'ero, I. Nuzzo, C. Bentivoglio, M. Galdiero, C. R. Carratelli, Effect of transforming growth factor β on experimental *Salmonella typhimurium* infection in mice, *Infect. Immun.*, **1999**, *67*, 1432-1438.

[2] L. Huang, F. Chen, Y. Chen, Y. Lin, J. T. Kung, Potent induction of long-term CD8⁺ T cell memory by short-term IL-4 exposure during T cell receptor stimulation, *Proc. Natl. Acad. Sci. USA.*, **2000**, *97*, 3406-3411.